- Home
- CALX vs RCKT Comparison
CALX vs RCKT Comparison
Compare CALX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALX
- RCKT
- Stock Information
- Founded
- CALX 1999
- RCKT 1999
- Country
- CALX United States
- RCKT United States
- Employees
- CALX N/A
- RCKT N/A
- Industry
- CALX Telecommunications Equipment
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- CALX Consumer Discretionary
- RCKT Health Care
- Exchange
- CALX Nasdaq
- RCKT Nasdaq
- Market Cap
- CALX 2.9B
- RCKT 264.0M
- IPO Year
- CALX 2010
- RCKT N/A
- Fundamental
- Price
- CALX $50.28
- RCKT $2.81
- Analyst Decision
- CALX Strong Buy
- RCKT Buy
- Analyst Count
- CALX 6
- RCKT 13
- Target Price
- CALX $48.20
- RCKT $18.50
- AVG Volume (30 Days)
- CALX 624.9K
- RCKT 3.6M
- Earning Date
- CALX 07-21-2025
- RCKT 08-04-2025
- Dividend Yield
- CALX N/A
- RCKT N/A
- EPS Growth
- CALX N/A
- RCKT N/A
- EPS
- CALX N/A
- RCKT N/A
- Revenue
- CALX $825,450,000.00
- RCKT N/A
- Revenue This Year
- CALX $10.71
- RCKT N/A
- Revenue Next Year
- CALX $9.93
- RCKT N/A
- P/E Ratio
- CALX N/A
- RCKT N/A
- Revenue Growth
- CALX N/A
- RCKT N/A
- 52 Week Low
- CALX $28.61
- RCKT $2.19
- 52 Week High
- CALX $54.07
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- CALX 54.80
- RCKT 41.85
- Support Level
- CALX $50.05
- RCKT $2.76
- Resistance Level
- CALX $54.07
- RCKT $3.24
- Average True Range (ATR)
- CALX 1.16
- RCKT 0.19
- MACD
- CALX -0.38
- RCKT 0.13
- Stochastic Oscillator
- CALX 26.27
- RCKT 49.10
About CALX Calix Inc
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.